Rigorous testing of cell therapies in South America struggles with emerging opportunities and regulatory deficiencies. As in other continents, these tend to be permissive with commercial opportunism but stifling for research. We describe a successful biotechnological entrepreneurship, born from within an academic institution, to foster science and promote translational research. Sustainability, however, requires a more complex niche, and realistic contributions from investors, state agencies, and legislators. An added level of complexity is required to enable multicentric studies. Herein we succinctly describe some of the most urgent challenges that the deployment of cell therapy faces in Chile. If this is truly an aspiration, fantasy should not be allowed to direct regulatory agents or legislators, and our Latin American Magic realism should remain within the realm of literary fiction.
Subscribe to Journal
Get full journal access for 1 year
only $68.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow derived myogenic progenitors. Science. 1998;279:152830.
Mezey E, Chandross KJ, Harta G, Maki RA, Mc Kercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science. 2000;290:177982
Caplan AI. What’s in a name? Tissue Eng Part A. 2010;16:2415–7.
Cynthia Nicole Padilla Muñoz. Ley Ricarte Soto y la Investigación Clínica en Chile (Departamento de Ciencias y Tecnologías Farmacéuticas Novartis SA, Facultad de Ciencias Químicas y Farmacéticas, Universidad de Chile, Santiago, 2017) .
Fagan A E Looking into a speaking mirror: politics, interpretation, and the English translation of ‘One Hundred Years of Solitude.’ J. Midwest Modern Language Assoc. 41 2008; 41: 46–55. www.jstor.org/stable/20464249.
Consorcio Regenero, The Chilean Stem Cell and Regenerative Medicine Consortium. No. 13 CTI-21522 (9 September 2013)
Matas J, Orrego M, Amenábar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord derived mesenchymal stromal cells for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Transl Med. 2019;8:215–24.
Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzúa E, Goset C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121:1192–204.
March KL, Pepine CJ. Cardiac cell therapy evolving from complex to straightforward: enabling adoption and affordability. Circ Res. 2017;121:1116–8.
Leal L. Magical Realism in Spanish America in MR: theory, history, community, (eds) Zamora LP, and Faris WB 1995, London, Duke University Press, pp120 –124. 1967.
Conflict of interest
MK is funded by Consorcio Regenero and “Cells for Cells”. FEF is the Principal Investigator of a Clinical Trial funded by Consorcio Regenero.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.